[ad_1]
VANCOUVER, BC and PRINCETON, NJ / ACCESSWIRE / March 22, 2022 / Xybion Digital Inc. (TSXV:XYBN) (“Xybion” or the “Firm”), a worldwide, low-code SaaS firm that permits digital transformation in extremely regulated industries like Life Sciences, introduced right this moment that it has been awarded a 5-year multi-million US greenback contract by a number one world pharmaceutical firm with branches in over 100 nations. Xybion is deploying the Pristima XD module to standardize and simplify lab operations for the consumer. This win reinforces Xybion’s management place within the Life Sciences sector and validates the Firm’s technique of increasing its operations into new geographies globally.
“We’re excited to start working with one of many largest world pharmaceutical corporations on the earth. This win bolsters Xybion Digital’s monitor file as a trusted companion to giant multinationals working within the life sciences business,” mentioned, Dr. Pradip Banerjee, Chairman and CEO of Xybion Digital. “We’re exceptionally proud to have been chosen by this world-renowned pharmaceutical group as their companion for digital acceleration of lab operations. Our low-code platform is ideally suited to assist Life Sciences corporations overcome the challenges of digital transformation, and we sit up for serving to this group obtain their targets.”
About Xybion Digital Inc.
Xybion is a worldwide SaaS firm that helps enterprise life sciences organizations speed up new drug growth into accredited medicines which will save lives and maintain staff secure. We digitize drug analysis and growth, laboratory testing, regulatory approvals, and pharmaceutical manufacturing on a single, unified cloud platform that’s cost-effective, able to deploy, and simple to make use of. Xybion has over 160 purchasers in 29 nations utilizing its low-code software program to speed up timelines, enhance compliance, broaden capability, reduce working dangers, and cut back bills whereas maintaining staff secure.
Be taught extra about Xybion at https://www.xybion.com/
For additional info: For extra info concerning Xybion Digital Inc., please contact Pradip Banerjee, Chief Govt Officer, [email protected], 609-512-5790 x122
Neither TSX Enterprise Alternate nor its Regulation Providers Supplier (as that time period is outlined in insurance policies of the TSX Enterprise Alternate) accepts duty for the adequacy or accuracy of this launch.
Ahead-Trying Statements
Sure statements (“forward-looking statements“) on this information launch could include forward-looking info regarding regarding Xybion’s place within the life sciences sector, the providers to be carried out by Xybion as described above and the outcomes thereof, , plans associated to the Firm’s enterprise and different issues which will happen sooner or later, made as of the date of this information launch. In making the forward-looking statements included on this information launch, the Firm has utilized a number of materials assumptions, together with that Xybion will be capable to carry out its providers as at the moment anticipated. Though administration considers these assumptions to be affordable based mostly on info accessible to it, they might show to be incorrect.
Ahead-looking statements are topic to a wide range of recognized and unknown dangers, uncertainties and different elements which might trigger precise occasions or outcomes to vary from these expressed or implied by the forward-looking statements. Readers are cautioned to not place undue reliance on these forward-looking statements as quite a few vital elements might trigger the precise outcomes to vary materially from the expectations expressed in them. Such elements embrace, amongst others, the chance that the Firm could not be capable to carry out its providers as at the moment anticipated, that outcomes of such providers might not be in step with anticipated outcomes, or these described in disclosure paperwork filed by the Firm on SEDAR. There could be no assurance that forward-looking statements will show to be correct and precise outcomes and future occasions might differ materially from these anticipated in such statements. The Firm expressly disclaims any intention or obligation to replace or revise any forward-looking statements whether or not on account of new info, future occasions or in any other case, besides as in any other case required by relevant securities laws.
This information launch doesn’t represent a suggestion to promote or a solicitation of a suggestion to purchase any of the securities described herein in the USA. The securities described herein haven’t been registered underneath the USA Securities Act of 1933, as amended (the “U.S. Securities Act“), or any state securities regulation and might not be supplied or offered within the “United States”, as such time period is outlined in Regulation S promulgated underneath the U.S. Securities Act, except registered underneath the U.S. Securities Act and relevant state securities legal guidelines or an exemption from such registration necessities is accessible.
SOURCE: Xybion Digital Inc.
View supply model on accesswire.com:
https://www.accesswire.com/694166/Xybion-Digital-Inc-is-Awarded-a-5-12 months-Multi-Million-US-dollar-Contract-with-a-Main-International-Pharmaceutical-Firm-Headquartered-in-Europe
[ad_2]
Source link